Clene Inc. (CLNN) News
Filter CLNN News Items
CLNN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLNN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CLNN News From Around the Web
Below are the latest news stories about CLENE INC that investors may wish to consider to help them evaluate CLNN as an investment opportunity.
IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES - (NewMediaWire) - December 30, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidiary,... |
IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease TreatmentsThis article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES - (NewMediaWire) - December 19, 2024 - Clene (NASDAQ: CLNN) has announced a $10 million debt ... |
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior LoanSecures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt Improves cash position enabling Clene to generate the additional data to support the new drug application of CNM-Au8® for ALS via an accelerated regulatory pathwayCarries a 12% interest rate per annum and is secured by all assets of CleneIncludes conversion feature on 65% of the new debt facility at a fixed conversion price of $5.67, a 130% premium to Clene’s closing stock price on the day of signin |
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval PathwayThis article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES - (NewMediaWire) - December 11, 2024 - Clene (NASDAQ: CLNN) received FDA guidance on leveragi... |
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALSFDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented findingsFDA recommends a follow-up meeting to discuss in more detail the analyses needed to support the accelerated approval pathway Additional NfL biomarker collection and analyses are underway and planned to be completed during the second quarter of 2025Clene is proceeding with its New Drug Application (NDA) |
Clene price target lowered to $83 from $86 at CanaccordCanaccord analyst Sumant Kulkarni lowered the firm’s price target on Clene (CLNN) to $83 from $86 and keeps a Buy rating on the shares. The firm noted they reported results with the key update for that the company held its planned meeting with the FDA on Novemebr 01 to discuss the potential to file a new drug application (NDA) for CNM-Au8 (nanocrystalline gold) for amyotrophic lateral sclerosis (ALS) under an accelerated approval pathway. Canaccord noted the company did not provide any character |
Clene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsClene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutesCash, cash equivalents and marketable securities of $14.6 million as of September 30, 2024Amended debt agreement with Avenue Capital to defer principal payments and extend maturity of facility to second quarter of 2025Completed registered direct offering and concurrent private placements to raise $7 |
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA LeadershipThis article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES, CA - (NewMediaWire) - October 25, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidiar... |
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor ConferencesThis article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - (NewMediaWire) - October 21, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidia... |
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private PlacementsThis article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - (NewMediaWire) - October 11, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidia... |